Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.14. Epub 2022 Jul 4.ABSTRACTStatins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis. The incidence of rhabdomyolysis due to fibrates and statins is low (0.0028-0.0096%) when administered as monotherapy, however it increases to 0.015-0.021% when the drugs are used in combination. The mechanism underlying myotoxicity induced by the combination of statins and fibrates is yet unclear. Here, we investigated the mechanisms underlying induced myotoxicity in rat myoblasts L6 and differentiate...
Source: J Physiol Pharmacol - July 6, 2022 Category: Drugs & Pharmacology Authors: M Tsubaki T Takeda T Mastuda A Kimura M Yanae A Maeda T Hoshida K Tanabe S Nishida Source Type: research
Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer
Although targeting of the cholesterol pathway by statins prevents breast cancer development in mouse models, efficacy is not absolute. Therefore, the goal of this study is to investigate if the upregulation in... (Source: BMC Cancer)
Source: BMC Cancer - March 17, 2022 Category: Cancer & Oncology Authors: Anjana Bhardwaj, Matthew D. Embury, Zhenlin Ju, Jing Wang and Isabelle Bedrosian Tags: Research Source Type: research
Fluvastatin alleviates doxorubicin-induced cardiac and renal toxicity in rats via regulation of oxidative stress, inflammation, and apoptosis associated genes expressions
. (Source: Drug and Chemical Toxicology)
Source: Drug and Chemical Toxicology - February 25, 2022 Category: Toxicology Authors: G ökçe Ceren Kuşçu Çevik Gürel Aylin Buhur Nefise Ülkü Karabay Yavaşoğlu Timur K öse Altu ğ Yavaşoğlu Fatih Oltulu Source Type: research
Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-gamma production via metabolism-related compound library screening
In this study, by using a commercially available metabolism-related compound library, we initially screened the capacity of compounds to activate NK cells by determining the ratio of interferon-gamma (IFN-γ)+ NK cells by flow cytometry after the incubation of peripheral blood mononuclear cells (PBMCs) with IL-12 or IL-15 for 18 h. Our data showed that eight compounds (nafamostat mesylate (NM), loganin, fluvastatin sodium, atorvastatin calcium, lovastatin, simvastatin, rosuvastatin calcium, and pitavastatin calcium) and three compounds (NM, elesclomol, and simvastatin) increased the proportions of NK cells and CD3+ T cells...
Source: Cell Research - February 15, 2022 Category: Cytology Authors: Qinglan Yang Shuju Zhang Shuting Wu Baige Yao Lili Wang Yana Li Hongyan Peng Minghui Huang Qinghua Bi Peiwen Xiong Liping Li Yafei Deng Youcai Deng Source Type: research
